S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
S&P 500   4,247.89 (-0.60%)
DOW   33,370.72 (-0.74%)
QQQ   353.59 (-0.18%)
AAPL   170.10 (-1.08%)
MSFT   311.81 (-0.11%)
META   299.41 (+0.15%)
GOOGL   129.77 (+0.93%)
AMZN   125.16 (-0.65%)
TSLA   237.60 (-2.67%)
NVDA   419.22 (+0.03%)
NIO   8.35 (-0.71%)
BABA   85.75 (-0.19%)
AMD   97.53 (+1.64%)
T   14.81 (-1.40%)
F   12.34 (-0.72%)
MU   67.23 (-1.05%)
CGC   0.87 (-6.20%)
GE   111.15 (+1.11%)
DIS   79.38 (-0.84%)
AMC   7.79 (-1.52%)
PFE   32.00 (-1.23%)
PYPL   57.09 (-3.12%)
NFLX   378.79 (-0.12%)
NASDAQ:TENX

Tenax Therapeutics (TENX) Stock Forecast, Price & News

$0.30
+0.01 (+1.81%)
(As of 12:27 PM ET)
Compare
Today's Range
$0.30
$0.31
50-Day Range
$0.28
$0.41
52-Week Range
$0.25
$4.30
Volume
29,310 shs
Average Volume
1.85 million shs
Market Capitalization
$7.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Tenax Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,871.1% Upside
$6.00 Price Target
Short Interest
Healthy
0.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Tenax Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.46) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars


TENX stock logo

About Tenax Therapeutics (NASDAQ:TENX) Stock

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

TENX Price History

TENX Stock News Headlines

TENX - Tenax Therapeutics, Inc.
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
TENX: Prioritizing Levosimendan
Tenax Therapeutics Provides 2023 Business Update
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
TENX: Patents Guide the Way
TENX Tenax Therapeutics, Inc.
TENX: New Funding Puts Wind in the Sails
Triangle pharma raising millions amid uncertain future
Tenax Therapeutics Down 20% After Offering Gets Priced
Why Tenax Therapeutics Shares Are Gaining Today?
Why Is Tenax Therapeutics (TENX) Stock Up 149% Today?
TENX.OQ - | Stock Price & Latest News | Reuters
See More Headlines
Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TENX Company Calendar

Last Earnings
11/16/2021
Today
9/27/2023
Next Earnings (Estimated)
9/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TENX
Employees
7
Year Founded
1967

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+1,920.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-11,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.65 per share

Miscellaneous

Free Float
23,385,000
Market Cap
$7.09 million
Optionable
Not Optionable
Beta
2.07

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Christopher T. Giordano (Age 48)
    CEO, Pres & Director
    Comp: $563.04k
  • Mr. Eliot M. Lurier CPA (Age 65)
    CPA, Interim Chief Financial Officer
    Comp: $221.7k
  • Dr. Stuart Rich M.D. (Age 73)
    Chairman of Scientific Advisory Board, Chief Medical Officer & Director
    Comp: $416k
  • Ms. Nancy J. M. Hecox
    Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
  • Mr. Doug Randall
    Exec. VP of Commercial & Bus. Operations
  • Dr. Douglas Hay
    Sr. VP of Regulatory Affairs













TENX Stock - Frequently Asked Questions

Should I buy or sell Tenax Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TENX shares.
View TENX analyst ratings
or view top-rated stocks.

What is Tenax Therapeutics' stock price forecast for 2023?

2 Wall Street analysts have issued 1 year price targets for Tenax Therapeutics' stock. Their TENX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,920.2% from the stock's current price.
View analysts price targets for TENX
or view top-rated stocks among Wall Street analysts.

How have TENX shares performed in 2023?

Tenax Therapeutics' stock was trading at $2.2280 at the start of the year. Since then, TENX shares have decreased by 86.7% and is now trading at $0.2970.
View the best growth stocks for 2023 here
.

When is Tenax Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, September 28th 2023.
View our TENX earnings forecast
.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its quarterly earnings results on Tuesday, November, 16th. The specialty pharmaceutical company reported ($3.00) EPS for the quarter, missing the consensus estimate of ($2.60) by $0.40.

When did Tenax Therapeutics' stock split?

Tenax Therapeutics shares reverse split on Wednesday, January 4th 2023. The 1-20 reverse split was announced on Wednesday, January 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

How do I buy shares of Tenax Therapeutics?

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tenax Therapeutics' stock price today?

One share of TENX stock can currently be purchased for approximately $0.30.

How much money does Tenax Therapeutics make?

Tenax Therapeutics (NASDAQ:TENX) has a market capitalization of $7.09 million.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The official website for the company is www.tenaxthera.com. The specialty pharmaceutical company can be reached via phone at 919-855-2100, via email at jesse@sternir.com, or via fax at 919-855-2133.

This page (NASDAQ:TENX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -